Skip to main
DXCM

DexCom (DXCM) Stock Forecast & Price Target

DexCom (DXCM) Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 48%
Buy 38%
Hold 10%
Sell 5%
Strong Sell 0%

Bulls say

DexCom's stock outlook remains positive due to a strong 22% year-over-year growth in international revenue, supported by successful market expansions in France and Canada. The company's domestic revenue also showed robust performance, increasing 21% year-over-year and capturing a larger share of the Type 2 diabetes market, which positions DexCom favorably for future growth. Additionally, management's raised full-year sales guidance, anticipating $4.630B-$4.650B, reflects confidence in the ongoing impact of pipeline innovations and expanded coverage, which are expected to drive significant market penetration and profitability.

Bears say

DexCom is lowering its profitability outlook for the year, reflecting concerns about the company's business quality and the impact of increased competition and integration challenges with insulin pumps. The adjusted EBIT and EBITDA expectations have decreased by 50 basis points to 20%-21% and 29%-30%, while the gross margin forecast has also dropped to 61% due to issues related to scrap rates and sensor quality. Furthermore, management's decision to revise future sales growth forecasts to approximately 12% and 13% for 2026 and 2027 suggests a cautious outlook amid operational challenges and intensifying competition in the continuous glucose monitoring market.

DexCom (DXCM) has been analyzed by 21 analysts, with a consensus rating of Buy. 48% of analysts recommend a Strong Buy, 38% recommend Buy, 10% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of DexCom and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About DexCom (DXCM) Forecast

Analysts have given DexCom (DXCM) a Buy based on their latest research and market trends.

According to 21 analysts, DexCom (DXCM) has a Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $85.05, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $85.05, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

DexCom (DXCM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.